Clinical trial
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg…
NCT00441350 · Menarini Group, Industry · Completed
Key facts
| NCT number | NCT00441350 |
|---|---|
| Title | Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension |
| Official title | Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension |
| Lead sponsor | Menarini Group, Industry |
| Collaborators | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | OM 40, OM/HCTZ 40/12.5 |
| Enrollment | 1,004 |
| Start date | Jul 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Feb 28, 2007 |
| Last update posted | Jul 28, 2021 |
| Countries | Croatia, Czechia, Denmark, Germany, Israel, Italy, Poland, Romania |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: